148 related articles for article (PubMed ID: 24722163)
1. Experience with erlotinib in lung adenocarcinoma harboring a coexisting KIF5B-RET fusion gene and EGFR mutation: report of a rare case.
Hirai F; Takenoyama M; Taguchi K; Toyozawa R; Inamasu E; Toyokawa G; Yoshida T; Shiraishi Y; Takenaka T; Yamaguchi M; Ushijima C; Seto T; Takeo S; Ichinose Y
J Thorac Oncol; 2014 May; 9(5):e37-9. PubMed ID: 24722163
[No Abstract] [Full Text] [Related]
2. Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21.
Lim SH; Lee JY; Sun JM; Ahn JS; Park K; Ahn MJ
J Thorac Oncol; 2014 Apr; 9(4):506-11. PubMed ID: 24736073
[TBL] [Abstract][Full Text] [Related]
3. Good response to gefitinib in lung adenocarcinoma harboring coexisting EML4-ALK fusion gene and EGFR mutation.
Kuo YW; Wu SG; Ho CC; Shih JY
J Thorac Oncol; 2010 Dec; 5(12):2039-40. PubMed ID: 21102267
[No Abstract] [Full Text] [Related]
4. First case of A859T epidermal growth factor receptor mutation responding to erlotinib.
Le Maignan L; Mirebeau-Prunier D; Vervueren L; Jeanfaivre T; Urban T; Hureaux J
J Thorac Oncol; 2011 Mar; 6(3):639-40. PubMed ID: 21317745
[No Abstract] [Full Text] [Related]
5. An uncommon insertion mutation in exon 19 of EGFR showed stable disease after TKI treatment.
Chan AW; Tong JH; Lo SH; To KF
J Thorac Oncol; 2013 Dec; 8(12):e107-8. PubMed ID: 24389445
[No Abstract] [Full Text] [Related]
6. Activity of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring rare epidermal growth factor receptor mutations.
De Pas T; Toffalorio F; Manzotti M; Fumagalli C; Spitaleri G; Catania C; Delmonte A; Giovannini M; Spaggiari L; de Braud F; Barberis M
J Thorac Oncol; 2011 Nov; 6(11):1895-901. PubMed ID: 21841502
[TBL] [Abstract][Full Text] [Related]
7. Lung adenocarcinoma with good response to erlotinib after gefitinib treatment failure and acquired T790M mutation.
Wu SG; Shih JY; Yu CJ; Yang PC
J Thorac Oncol; 2008 Apr; 3(4):451-2. PubMed ID: 18379370
[No Abstract] [Full Text] [Related]
8. Two generations of light/never-smokers with advanced adenocarcinoma of the lung with durable responses to erlotinib.
Pennell NA; Yin L; Keshtgarpour M; Ma PC
J Thorac Oncol; 2012 Jul; 7(7):1200-1. PubMed ID: 22706608
[No Abstract] [Full Text] [Related]
9. Favorable response to erlotinib in a lung adenocarcinoma with both epidermal growth factor receptor exon 19 deletion and K-ras G13D mutations.
Lee CN; Chen HY; Liu HE
J Clin Oncol; 2010 Mar; 28(7):e111-2. PubMed ID: 20008635
[No Abstract] [Full Text] [Related]
10. The utility of molecular testing in the futility of definite therapy.
Joshi A; Noronha V; Ghosh J; Prabhash K
Indian J Cancer; 2014; 51(4):409. PubMed ID: 26842138
[No Abstract] [Full Text] [Related]
11. A phase II trial of erlotinib monotherapy in pretreated patients with advanced non-small cell lung cancer who do not possess active EGFR mutations: Okayama Lung Cancer Study Group trial 0705.
Yoshioka H; Hotta K; Kiura K; Takigawa N; Hayashi H; Harita S; Kuyama S; Segawa Y; Kamei H; Umemura S; Bessho A; Tabata M; Tanimoto M;
J Thorac Oncol; 2010 Jan; 5(1):99-104. PubMed ID: 19898258
[TBL] [Abstract][Full Text] [Related]
12. [Personalized treatment in non-small cell lung cancer].
Campos-Parra AD; Cruz-Rico G; Arrieta O
Rev Invest Clin; 2012; 64(4):377-86. PubMed ID: 23227588
[No Abstract] [Full Text] [Related]
13. Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib.
Katayama T; Shimizu J; Suda K; Onozato R; Fukui T; Ito S; Hatooka S; Sueda T; Hida T; Yatabe Y; Mitsudomi T
J Thorac Oncol; 2009 Nov; 4(11):1415-9. PubMed ID: 19692934
[TBL] [Abstract][Full Text] [Related]
14. Lung adenocarcinoma with concurrent exon 19 EGFR mutation and ALK rearrangement responding to erlotinib.
Popat S; Vieira de Araújo A; Min T; Swansbury J; Dainton M; Wotherspoon A; Lim E; Nicholson AG; O'Brien ME
J Thorac Oncol; 2011 Nov; 6(11):1962-3. PubMed ID: 22005476
[No Abstract] [Full Text] [Related]
15. EGFR mutations in squamous cell lung cancer in never-smokers.
Baik CS; Pritchard CC; Eaton KD; Chow LQ
J Thorac Oncol; 2013 Jan; 8(1):e6-7. PubMed ID: 23242446
[No Abstract] [Full Text] [Related]
16. Optimising therapy for EGFR-addicted NSCLC: just the start.
Govindan R; Subramanian J
Lancet Oncol; 2012 Mar; 13(3):216-7. PubMed ID: 22285167
[No Abstract] [Full Text] [Related]
17. [About new treatments in thoracic oncology].
Couraud S
Rev Pneumol Clin; 2013 Apr; 69(2):63-4. PubMed ID: 23434002
[No Abstract] [Full Text] [Related]
18. Cytokeratin 19 fragment predicts the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitor in non-small-cell lung cancer harboring EGFR mutation.
Tanaka K; Hata A; Kaji R; Fujita S; Otoshi T; Fujimoto D; Kawamura T; Tamai K; Takeshita J; Matsumoto T; Monden K; Nagata K; Otsuka K; Nakagawa A; Tachikawa R; Otsuka K; Tomii K; Katakami N
J Thorac Oncol; 2013 Jul; 8(7):892-8. PubMed ID: 23591159
[TBL] [Abstract][Full Text] [Related]
19. Complete pathologic response in lung tumors in two patients with metastatic non-small cell lung cancer treated with erlotinib.
Weber B; Sorensen BS; Knap MM; Madsen HH; Nexo E; Meldgaard P
J Thorac Oncol; 2011 Nov; 6(11):1946-9. PubMed ID: 22005472
[TBL] [Abstract][Full Text] [Related]
20. Erlotinib, gefitinib, or chemotherapy for EGFR mutation-positive lung cancer?
Mitsudomi T
Lancet Oncol; 2011 Aug; 12(8):710-1. PubMed ID: 21783418
[No Abstract] [Full Text] [Related]
[Next] [New Search]